RxDoctor Payments DataLook up a doctor →

Susan Orr, PA

Physician Assistant · Maryville, TNNPI 1184803603

Payments from drug & device makers

$14,932in general payments, 2019–2025

Across 782 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$2K
  • Harmony Biosciences LLC$1K
  • Insmed, Inc.$1K
  • Boehringer Ingelheim$993
  • Grifols USA, LLC$851
  • plus $6K from 35 others

What the payments were for

  • Food & beverage$14,71099%
  • Education$2221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,932 in reported general payments places this provider in the 95th percentile of 2,404 physician assistant providers in Tennessee.

See all physician assistant providers in Tennessee

Medicare billing

Part B allowed, 2024
$58,008
Medicare patients
459
Services billed
826

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter267$295,152
OfevNintedanib Esylate20$257,851
Breo ElliptaFluticasone/Vilanterol117$66,561
Breztri AerosphereBudesonide/Glycopyr/Formoterol65$53,527
Stiolto RespimatTiotropium Br/Olodaterol Hcl70$50,695
SymbicortBudesonide/Formoterol Fumarate69$25,384
EliquisApixaban29$24,896
Spiriva RespimatTiotropium Bromide21$19,930
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr24$18,659
Albuterol Sulfate HfaAlbuterol Sulfate406$11,026
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate41$8,036
QuviviqDaridorexant Hcl17$7,999
Armodafinil57$3,513
Ventolin HfaAlbuterol Sulfate32$3,437
Modafinil92$3,105

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,950$380,373408 claims
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat$993$328,476111 claims
AstraZenecaBreztri Aerosphere, Symbicort$2,308$78,910134 claims
PfizerEliquis$16$24,89629 claims
Idorsia Pharmaceuticals US IncQuviviq$14$7,99917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,404 physician assistant providers in Tennessee.

Other physician assistant in Maryville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →